The presence of bone metastasis is also associated with poor prognosis in RCC.33 Recent data have shown notable cabozantinib activity in this subgroup of patients.34 This might be explained by the key role of c-MET in modulating the activity of osteoblasts and osteoclasts. This evidence concerns the gene MET and renal cell carcinoma.